Relapsing Multiple Sclerosis Clinical Trial Pipeline Analysis: 25+ Key Companies Transforming the Future of RMS Therapeutics | DelveInsight

DelveInsight's Relapsing Multiple Sclerosis Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline therapies for Relapsing Multiple Sclerosis in various stages of clinical development. Major pharmaceutical and biotechnology companies are actively working to advance the Relapsing Multiple Sclerosis pipeline space and strengthen the future growth potential of the RMS therapeutics market.

Key takeaways from the Relapsing Multiple Sclerosis Clinical Trial Landscape Report
• DelveInsight's Relapsing Multiple Sclerosis pipeline report depicts a robust therapeutic landscape with 25+ active companies developing therapies for Relapsing Multiple Sclerosis treatment.
• Key Relapsing Multiple Sclerosis companies such as Sanofi, Novartis, Roche, Cabaletta Bio, Zenas BioPharma, Eli Lilly and Company, and others are actively evaluating innovative therapies in the RMS pipeline market.
• Promising Relapsing Multiple Sclerosis pipeline therapies in different stages of development include Remibrutinib, Tolebrutinib, Obexelimab, CABA-201, RO7121932, SAR441344, and others.

Request a sample and discover the recent advances in Relapsing Multiple Sclerosis treatment therapies.https://www.delveinsight.com/sample-request/relapsing-remitting-multiple-sclerosis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Relapsing Multiple Sclerosis?
Multiple sclerosis (MS) is the most common neurological disorder in young adults and generally appears between the ages of 20 and 40 years. The disease damages the myelin sheath of the central nervous system (CNS), leading to the formation of scarred plaques visible on MRI scans. These lesions contribute to symptoms including vision problems, numbness, fatigue, spasticity, cognitive impairment, and bladder or bowel dysfunction.
Relapsing-remitting multiple sclerosis (RRMS), the most common form of MS, is characterized by episodes of neurological flare-ups followed by periods of remission. Approximately 65% of patients with RRMS eventually progress to secondary progressive multiple sclerosis (SPMS), resulting in gradual disability progression. Risk factors associated with multiple sclerosis include environmental factors, obesity, genetics, autoimmune diseases, smoking, and infections. Diagnosis relies on clinical history, neurological examination, MRI findings, and cerebrospinal fluid (CSF) analysis.

Emerging Relapsing Multiple Sclerosis Drug Profiles
SAR441344: Sanofi
SAR441344 (Frexalimab) is a CD40L monoclonal antibody being developed by Sanofi and ImmuNext for autoimmune disorders including Relapsing Multiple Sclerosis. The therapy blocks the CD40L-CD40 interaction responsible for triggering heightened T-cell immune responses associated with autoimmune diseases. The therapy is currently being evaluated in Phase III clinical development for Relapsing Multiple Sclerosis.
In December 2023, Sanofi initiated a Phase III trial evaluating the efficacy and safety of Frexalimab compared to teriflunomide in adult patients with relapsing forms of multiple sclerosis. The study is anticipated to be completed by May 2027 with an estimated enrollment of 1600 participants.
Obexelimab: Zenas BioPharma
Obexelimab is a monoclonal antibody therapy being developed by Zenas BioPharma for Relapsing Multiple Sclerosis. The therapy is currently in Phase II clinical development and is administered subcutaneously.
In October 2025, Zenas BioPharma announced positive Phase II MoonStone trial results for obexelimab in Relapsing Multiple Sclerosis. The therapy demonstrated a statistically significant 95% relative reduction in the cumulative number of new gadolinium-enhancing T1 hyperintense lesions compared with placebo.

Recent Developments in the Relapsing Multiple Sclerosis Clinical Trial Landscape
• In October 2025, Zenas BioPharma announced positive Phase II MoonStone trial results of obexelimab in Relapsing Multiple Sclerosis, demonstrating a statistically significant reduction in new gadolinium-enhancing lesions.
• In June 2025, Immunic, Inc. announced completion of enrollment for both Phase III ENSURE trials evaluating vidofludimus calcium (IMU-838) in patients with Relapsing Multiple Sclerosis.
• In December 2023, Sanofi initiated a Phase III clinical trial evaluating Frexalimab (SAR441344) in patients with relapsing forms of multiple sclerosis.
Scope of the Relapsing Multiple Sclerosis Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination
• Therapeutic Assessment By Clinical Stages: Phase I, Phase I/II, Phase II, Phase III, Preclinical
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Intravenous/Subcutaneous
• Therapeutics Assessment By Molecule Type: Small molecule, Monoclonal antibody, CAR-T cell therapy, Antibody
• Key Relapsing Multiple Sclerosis Companies: Sanofi, Novartis, Roche, Cabaletta Bio, Zenas BioPharma, Eli Lilly and Company, and others
• Key Relapsing Multiple Sclerosis Pipeline Therapies: Remibrutinib, Tolebrutinib, Obexelimab, CABA-201, RO7121932, SAR441344, and others

Dive deep into rich insights for new drugs for Relapsing Multiple Sclerosis treatment. https://www.delveinsight.com/sample-request/relapsing-remitting-multiple-sclerosis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. Relapsing Multiple Sclerosis Pipeline Report Introduction
2. Relapsing Multiple Sclerosis Pipeline Report Executive Summary
3. Relapsing Multiple Sclerosis: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Relapsing Multiple Sclerosis Pipeline Therapeutics
6. Relapsing Multiple Sclerosis Pipeline: Late Stage Products (Phase III)
7. Relapsing Multiple Sclerosis Pipeline: Mid Stage Products (Phase II/III)
8. Relapsing Multiple Sclerosis Pipeline: Mid Stage Products (Phase II)
9. Relapsing Multiple Sclerosis Pipeline: Early Stage Products (Phase I/II)
10. Relapsing Multiple Sclerosis Pipeline: Early Stage Products (Phase I)
11. Relapsing Multiple Sclerosis Pipeline: Preclinical Stage Products
12. Relapsing Multiple Sclerosis Pipeline Therapeutics Assessment
13. Inactive Products in the Relapsing Multiple Sclerosis Pipeline
14. Company-University Collaborations (Licensing/Partnering/Funding) Analysis
15. Key Companies
16. Key Products in the Relapsing Multiple Sclerosis Pipeline
17. Unmet Needs
18. Market Drivers and Barriers
19. Future Perspectives and Conclusion
20. Analyst Views
21. Appendix

For further information on the Relapsing Multiple Sclerosis pipeline therapeutics, reach out to DelveInsight. https://www.delveinsight.com/sample-request/relapsing-remitting-multiple-sclerosis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical and biotechnology companies by providing comprehensive end-to-end solutions to improve business performance. DelveInsight offers market research reports, pipeline analysis, competitive intelligence, and forecasting solutions through its subscription-based platform PharmDelve.

This release was published on openPR.